We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biomarkers Predict Kidney Problems After Cardiac Surgery

By LabMedica International staff writers
Posted on 13 Mar 2012
Blood and urine markers can indicate which patients with an abrupt kidney injury following heart surgery will experience progressive kidney problems.

Until now, doctors have not been able to determine which cases of acute kidney injury (AKI) that develop after heart surgery will worsen so testing for these markers soon after surgery could help doctors protect the health of patients' kidneys. More...


At Yale University School of Medicine (New Haven, CT, USA) investigators found that the presence of certain markers on the day that AKI is diagnosed can indicate structural injury to the kidneys that will likely cause patients to experience progressive problems. They prospectively enrolled 1,219 adults undergoing cardiac surgery (coronary artery bypass grafting or valve surgery) who were at high risk for AKI at six academic medical centers in North America between July of 2007 and December of 2009. Urine and plasma specimens collected preoperatively and daily for up to five postoperative days.

High urinary interleukin-18 (IL-18) and the albumin-to-creatinine ratio (ACR) increased patients' risk of experiencing persistent AKI by approximately three-fold, while high blood levels of a protein called neutrophil gelatinase-associated lipocalin (NGAL) increased their risk by more than seven-fold. Urine IL-18 and NGAL were measured with the ARCHITECT assay (Abbott Diagnostics, Abbott Park, IL, USA). Plasma NGAL was measured through the Triage NGAL immunoassay in conjunction with the TriageMeter (Biosite Inc., San Diego, CA, USA).

The authors concluded that urinary IL-18, ACR, and plasma NGAL measurement at the time of clinical creatinine increase forecasted the progression of AKI in adults after cardiac surgery. Chirag Parikh, MD, PhD, a lead author of the study said, "Our multicenter study is the largest acute kidney injury biomarker study performed to date in adults, and it strengthens the new paradigm that assessing structural injury at the time of clinical diagnosis with urine or blood markers of kidney injury can yield important prognostic information." The study was published online on March 1, 2012, in the Journal of the American Society Nephrology.

Related Links:

Yale University School of Medicine
Abbott Diagnostics
Biosite Inc



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Automatic CLIA Analyzer
Shine i6000
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image

FDA Breakthrough-Designated Urine Panel Aims to Shorten Pathogen and Susceptibility Testing

Urinary tract infections are among the most common bacterial infections and a major driver of antibiotic prescribing, yet culture-based workflows can take days to produce results. Treatment often begins... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.